Answers are grounded in this paper and cite their sources.
Critical issues in determining therapeutic strategies for patients with myelodysplastic syndromes (MDSs), who usually die of bone marrow failure with or without conversion to acute myeloid leukemia (AML), include host factors in these mainly older patients, disease heterogeneity, lack of
No takes yet. Share an insight, caveat, or question.
Richard M. Stone (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: